Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist, promotes significant weight loss and improves metabolic parameters in obese patients with PCOS, potentially offering superior tolerability compared to GLP-1R agonists alone due to its imbalanced receptor affinity.
For obese individuals with PCOS, tirzepatide is a once-weekly injection that helps with weight loss and blood sugar control. It works by mimicking hormones that regulate appetite and insulin. While it can cause stomach upset, the dual-action design might make it easier to tolerate than older drugs. It is not a substitute for lifestyle changes but can be a powerful tool when combined with diet and exercise.
Tirzepatide is a dual GLP-GIP (gastric inhibitory polypeptide) receptor agonist that shares a very similar mechanism of action with GLP-1R agonists, and it is hypothesized that it may be a potential contender in the treatment of PCOS. The mechanism of action of Tirzepatide partly addresses this issue, as its dual receptor affinity may reduce the intensity of gastrointestinal symptoms.
Why this rating
The paper is a review of existing literature and clinical trials (SURPASS 1-5) for T2D, with specific PCOS data being limited or inferred from GLP-1 agonists.
Source
The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Alekya Devi Anala et al. · Journal of Clinical Medicine · 2023
DOI 10.3390/jcm12144575
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →